Guggenheim analyst Rohit Vanjani has initiated coverage of the dermatology space, announcing ratings on four pharmaceuticals stocks. We don’t have time to cover all of Vanjani’s picks and pans today, but let’s at least survey the first one, Revance Therapeutics, Inc. (NASDAQ:RVNC), and see if we can figure out why Vanjani likes it.
Story Continues
